Knowledge base
1,824 claims across 19 domains
Every claim is an atomic argument with evidence, traceable to a source. Browse by domain or search semantically.
All 1,824ai alignment 395health 320internet finance 306space development 227entertainment 169grand strategy 141collective intelligence 52mechanisms 34teleological economics 30living agents 30cultural dynamics 29critical systems 24energy 23teleohumanity 18living capital 10robotics 5manufacturing 5unknown 3technology 3
OBBBA SNAP cuts represent the largest food assistance reduction in US history at $186 billion through 2034, removing continuous nutritional support from 2.4 million people despite evidence that SNAP participation reduces healthcare costs by 25 percent
OBBBA's SNAP provisions cut $186 billion through 2034 through Thrifty Food Plan formula adjustments and work requirement expansions, making this the largest food assistance reduction in US history. The cuts are projected to remove 2.4 million people from SNAP by 2034, with more than 1 million older
OBBBA SNAP cost-shifting to states creates a fiscal cascade where compliance with federal work requirements imposes $15 billion annual state costs, forcing states to cut additional health benefits to absorb the new burden
OBBBA shifts SNAP costs to states, with Pew analysis projecting states' collective SNAP costs will rise $15 billion annually once phased in. This creates a fiscal cascade mechanism: states facing dual cost pressure from new SNAP state share requirements and new Medicaid administrative requirements (
Semaglutide produces superior cardiovascular outcomes compared to tirzepatide despite achieving less weight loss because GLP-1 receptor-specific cardiac mechanisms operate independently of weight reduction
The STEER study compared semaglutide to tirzepatide in 10,625 matched patients with overweight/obesity and established ASCVD without diabetes. Semaglutide demonstrated 29% lower risk of revised 3-point MACE and 22% lower risk of revised 5-point MACE compared to tirzepatide, with per-protocol analysi
Long-term US cardiovascular mortality gains are slowing or reversing across major conditions as of 2026 after decades of continuous improvement
The JACC 2026 Cardiovascular Statistics report documents that long-term mortality gains are 'slowing or reversing' across coronary heart disease, acute MI, heart failure, peripheral artery disease, and stroke. Heart failure mortality specifically has been increasing since 2012 and is now 3% higher t
Double coverage compression occurs when Medicaid work requirements contract coverage below 138 percent FPL while APTC expiry eliminates subsidies for 138-400 percent FPL simultaneously
OBBBA creates what can be termed 'double coverage compression'—the simultaneous contraction of both major coverage pathways for low-income populations. Medicaid work requirements affect populations below 138% FPL (the Medicaid expansion threshold), while APTC (Advance Premium Tax Credits) expired in
GLP-1 receptor agonists produce nutritional deficiencies in 12-14 percent of users within 6-12 months requiring monitoring infrastructure current prescribing lacks
A large cohort study of 461,382 GLP-1 users found that 12.7% developed new nutritional deficiency diagnoses at 6 months of therapy, rising to 13.6% for vitamin D deficiency by 12 months. Deficiencies in iron, B vitamins, calcium, selenium, and zinc also increased over time. The mechanism is straight
GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management
BCBS Health Institute and Prime Therapeutics analyzed real-world commercial insurance data showing one-year persistence rates for obesity-indicated, high-potency GLP-1 products increased from 33.2% in 2021 to 34.1% in 2022, 40.4% in 2023, and 62.6% in 2024. Semaglutide (Wegovy) specifically tracked
GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements
Despite the near-doubling of year-one persistence rates, Prime Therapeutics data shows only 14% of members newly initiating a GLP-1 for obesity without diabetes were persistent at two years (1 in 7). Three-year data from earlier cohorts shows further decline to approximately 8-10%. The striking dive
OBBBA Medicaid work requirements destroy the enrollment stability that value-based care requires for prevention ROI by forcing all 50 states to implement 80-hour monthly work thresholds by December 2026
OBBBA requires all states to implement Medicaid work requirements (80+ hours/month for ages 19-64) by December 31, 2026, with CMS issuing implementation guidance by June 1, 2026. This creates a structural conflict with value-based care economics. VBC models require 12-36 month enrollment stability t
All three major clinical AI regulatory tracks converged on adoption acceleration rather than safety evaluation in Q1 2026
The UK House of Lords Science and Technology Committee launched its NHS AI inquiry on March 10, 2026, with explicit framing as an adoption failure investigation: 'Why does the NHS adoption of the UK's cutting-edge life sciences innovations often fail, and what could be done to fix it?' The inquiry e
Regulatory vacuum emerges when deregulation outpaces safety evidence accumulation creating institutional epistemic divergence between regulators and health authorities
The simultaneous release of the EU Commission's proposal to ease AI Act requirements for medical devices and WHO's explicit warning of 'heightened patient risks due to regulatory vacuum' documents a regulator-vs.-regulator split at the highest institutional level. The Commission proposed postponing
US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics
WHO data shows US healthspan—years lived without significant disability—actually declined from 65.3 years in 2000 to 63.9 years in 2021, a loss of 1.4 healthy years. This occurred during the same period when life expectancy fluctuated but ultimately reached a record high of 79 years in 2024 accordin
Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036
Tirzepatide's patent protection extends significantly beyond semaglutide through a deliberate thicket strategy: primary compound patent expires 2036, with formulation and delivery device patents extending to approximately December 30, 2041. This contrasts sharply with semaglutide, which expired in I
LLM anchoring bias causes clinical AI to reinforce physician initial assessments rather than challenge them because the physician's plan becomes the anchor that shapes all subsequent AI reasoning
The GPT-4 anchoring study finding that 'incorrect initial diagnoses consistently influenced later reasoning' provides a cognitive architecture explanation for the clinical AI reinforcement pattern observed in OpenEvidence adoption. When a physician presents a question with a built-in assumption or i
Clinical AI that reinforces physician plans amplifies existing demographic biases at population scale because both physician behavior and LLM training data encode historical inequities
The Nature Medicine finding that LLMs exhibit systematic sociodemographic bias across all model types creates a specific safety concern for clinical AI systems designed to 'reinforce physician plans' rather than replace physician judgment. Research on physician behavior already documents demographic
Ultra-processed food consumption increases incident hypertension risk by 23% over 9 years through a chronic inflammation pathway that establishes food environment as a mechanistic driver not merely a poverty correlate
The REGARDS cohort tracked 5,957 adults free from hypertension at baseline for 9.3 years (2003-2016). Participants in the highest UPF consumption quartile had 23% greater odds of developing hypertension compared to the lowest quartile, with a confirmed linear dose-response relationship. 36% of the i
The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
The Mayo Clinic study examined healthspan-lifespan gaps across 183 WHO member states from 2000-2019 and found the United States has the largest gap globally at 12.4 years—meaning Americans live on average 12.4 years with significant disability and sickness. This exceeds other high-income nations: Au
Multi-agent clinical AI is being adopted for efficiency reasons not safety reasons, creating a situation where NOHARM's 8% harm reduction may be implemented accidentally via cost-reduction adoption
The Mount Sinai paper frames multi-agent clinical AI as an EFFICIENCY AND SCALABILITY architecture (65x compute reduction), while NOHARM's January 2026 study showed the same architectural approach reduces clinical harm by 8% compared to solo models. The Mount Sinai paper does not cite NOHARM's harm
CVD mortality stagnation after 2010 affects all income levels including the wealthiest counties indicating structural system failure not poverty correlation
The pervasive nature of CVD mortality stagnation across all income deciles—including the wealthiest counties—demonstrates this is a structural, system-wide phenomenon rather than a poverty-driven outcome. While county-level median household income was associated with the absolute level of CVD mortal
US CVD mortality is bifurcating with ischemic heart disease declining while heart failure and hypertensive disease reach all-time highs revealing that aggregate improvement masks structural deterioration in cardiometabolic health
The AHA 2026 report reveals a critical bifurcation in CVD mortality trends. While overall age-adjusted CVD mortality declined 33.5% from 1999 to 2023 (350.8 to 218.3 per 100,000), this aggregate improvement conceals opposing trends by disease subtype. Ischemic heart disease and cerebrovascular disea
CVD mortality stagnation drives US life expectancy plateau 3-11x more than drug deaths inverting the dominant opioid crisis narrative
NCI researchers quantified the contribution of different mortality causes to US life expectancy stagnation between 2010 and 2017. CVD stagnation held back life expectancy at age 25 by 1.14 years in both women and men. Rising drug-related deaths had a much smaller effect: 0.1 years in women and 0.4 y
Medical benchmark performance does not predict clinical safety as USMLE scores correlate only 0.61 with harm rates
The NOHARM study found that safety performance (measured as severe harm rate across 100 real clinical cases) correlated only moderately with existing AI and medical benchmarks at r = 0.61-0.64. This means that a model's USMLE score or performance on other medical knowledge tests explains only 37-41%
Provider tax freeze blocks state CHW expansion by eliminating the funding mechanism not the program because provider taxes fund 17 percent of state Medicaid share and CHW SPAs require state match
The OBBBA provider tax freeze creates a structural contradiction for CHW expansion: 20 states now have federal SPA approval for CHW reimbursement (as of March 2025), but provider taxes fund 17%+ of state Medicaid share nationally (30%+ in Michigan, NH, Ohio). States are prohibited from establishing
Ultra-processed food diets generate continuous inflammatory vascular damage that partially counteracts antihypertensive pharmacology explaining why 76.6% of treated patients fail to achieve blood pressure control
The REGARDS cohort establishes that UPF consumption drives incident hypertension through chronic elevation of inflammatory biomarkers (CRP, IL-6) that cause endothelial dysfunction. In food-insecure households, this creates a circular mechanism: (1) limited access to affordable non-UPF foods forces
Hypertension became the primary contributing cardiovascular cause of death in the US since 2022 marking a shift from acute ischemia to chronic metabolic disease as the dominant CVD mortality driver
Hypertensive disease age-adjusted mortality doubled from 15.8 to 31.9 per 100,000 between 1999-2023. Since 2022, hypertension has become the #1 contributing cardiovascular cause of death in the US, surpassing ischemic heart disease. This represents a fundamental epidemiological shift: the primary dr
Page 8 of 13